Article Text

Download PDFPDF
Successful treatment of multicentric Castleman's disease accompanying myeloma with bortezomib
  1. Afaq Ahmad Khan1,
  2. Fouzia Siraj2,
  3. Manorama Bhargava2,
  4. Shyam Aggarwal3
  1. 1Department of Haematology, Sir Ganga Ram Hospital, New Delhi, India
  2. 2Department of Pathology, Sir Ganga Ram Hospital, New Delhi, India
  3. 3Department of Medical Oncology, Sir Ganga Ram Hospital, New Delhi, India
  1. Correspondence to Dr Afaq Ahmad Khan, drafaqak{at}


Castleman's disease represents an atypical lymphoproliferative disorder which is non-clonal but can turn malignant in the form of lymphoma, Kaposi's sarcoma or plasma cell dyscrasia. It has been reported in association with diseases like polyneuropathy organomegaly endocrinopathy monoclonal gammopathy skin changes syndrome and myeloma and very rarely it can be associated with cutaneous vasculitis as in our case. It relatively runs an aggressive course and has a shorter survival. No standard of care therapy is yet established for multicentric Castleman's disease accompanying myeloma. We successfully treated one such patient with bortezomib-based therapy.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.